DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company, pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent, global challenge of antibiotic resistance, informs its shareholders that the Extraordinary Annual General Meeting (AGM) held on September 13, 2021 on a third convening has followed the recommendations of the Board of Directors, and adopted all the resolutions that the Board was favourable to, i.e. 11 out of the 12 resolutions.

The shareholders taking part in the vote owned collectively 3,473,086 shares with voting rights out of the 28,711,585 shares making up the share capital and carrying voting rights, i.e. 12.096% of the share capital.

Considering the appointment of Mr. Vincent AUSSEL in capacity of ad hoc representative (mandataire ad hoc), by order of the President of the Commercial Court of Montpellier dated June 30, 2021, with the mission to represent and act on behalf of the defaulting shareholders, the rights attached to the 25,238,499 shares of such shareholders were exercised by the ad hoc representative so that the quorum amounted to 100% of the 28,711,585 shares with voting rights. Consequently, the extraordinary resolutions have been debated as listed in the meeting notice published in the French official legal bulletin Bulletin des Annonces Légales Obligatoires (BALO) No. 102, dated August 25, 2021.

The voting rights attached to the shares of the defaulting shareholders represented by the ad hoc representative were exercised at a rate of two thirds votes in favour and one third against, pursuant to the terms of the mission entrusted to the ad hoc representative by order of the President of the Commercial Court of Montpellier dated June 30, 2021.

All the documents regarding this AGM, including the results of the votes, are available on the Company’s website: https://www.deinove.com/en/investors/documentation-center/shareholders-meetings/annual-shareholders-meeting-september-13-2021